Global Cyclic Neutropenia Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Global Cyclic Neutropenia Treatment Market Segmentation, By Treatment (Antibiotics, Corticosteroids, Granulocyte Colony-Stimulating Factor (G-CSF), Bone Marrow Transplant, Genetic Counseling, and Others), Diagnosis (Blood Tests, Genetic Test, and Others), Symptoms (Fever, Recurring Gum Problems and Loose Teeth, Skin Infections, Sore Throat, Lung Infections, Sores in the Mouth, Digestive System Infections, Fatigue, Overall Feeling of not Being Well, and Others), Dosage (Injection, Tablets, and Others), Route of Administration (Oral, Intravenous, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Industry Trends and Forecast to 2033

Cyclic Neutropenia Treatment Market Overview

The global Cyclic Neutropenia Treatment market was valued at USD 651.26 Million in 2025 and is projected to reach USD 1205.43 Million by 2033, growing at a CAGR of 8.00% from 2026 to 2033. The Global Cyclic Neutropenia Treatment Market is experiencing steady growth driven by increasing awareness of rare hematological disorders, rising diagnosis rates, and growing adoption of targeted biologic therapies such as granulocyte colony-stimulating factors (G-CSFs). Advancements in immunotherapy and supportive care treatments are further strengthening the therapeutic landscape.

The rising prevalence of genetic and autoimmune-related neutropenia cases, along with improved access to specialized hematology care, is encouraging early diagnosis and long-term disease management. In addition, expanding healthcare infrastructure and orphan drug incentives across major markets are supporting pharmaceutical innovation and increasing treatment accessibility for patients with cyclic neutropenia.

Key Market Trends & Insights

• North America dominated the global Cyclic Neutropenia Treatment market with the largest revenue share of 36.42% in 2025, supported by advanced healthcare infrastructure, strong orphan drug availability, and increasing adoption of biologic therapies
• The Granulocyte Colony-Stimulating Factor (G-CSF) segment led the market with a 44.18% share in 2025, driven by its high effectiveness in stimulating neutrophil production and reducing recurrent infections
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 7.4% from 2026 to 2033, fueled by improving healthcare access, rising awareness of rare blood disorders, and expanding diagnostic capabilities across China, India, and Japan
• The Genetic Test segment is the fastest-growing diagnosis type, projected to register a CAGR of 7.1%, reflecting increasing adoption of precision diagnostics and early detection of inherited neutropenia disorders
• The Hospital segment dominates the end-user category with a 48.05% revenue share in 2025, led by growing patient admissions, availability of specialized hematology care, and access to advanced biologic treatment options
• Hospital Pharmacy accounts for 55.12% of the market, preferred for the dispensing of injectable biologics and supportive therapies requiring clinical supervision and continuous monitoring
• The Injection segment is the fastest-growing dosage category, with a CAGR of 6.9%, driven by rising use of injectable G-CSF therapies for long-term cyclic neutropenia management
• The Intravenous segment dominated the market with a share of 57.89% in 2025 due to its high effectiveness in delivering rapid therapeutic response during severe infection episodes and neutropenia management

Market Size & Forecast

• Global Market Value (2025): USD 651.26 Million
• Expected Market Value (2033): USD 1205.43 Million
• Forecast CAGR (2026–2033): 8.00%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Global Cyclic Neutropenia Treatment Market Segmentation

Global Cyclic Neutropenia Treatment Market Trends

Trend: Rising Adoption of Targeted Biologic Therapies and Genetic Testing

Healthcare providers are increasingly adopting targeted biologic therapies such as Granulocyte Colony-Stimulating Factor (G-CSF) for the long-term management of cyclic neutropenia, helping reduce infection frequency and improve neutrophil recovery. The growing use of genetic testing is also enabling earlier and more accurate diagnosis of inherited neutropenia disorders. According to rare disease research initiatives and hematology associations, ELANE gene mutations remain one of the primary causes of cyclic neutropenia, driving demand for precision diagnostics and personalized treatment strategies. In addition, specialty hematology centers are increasingly integrating molecular diagnostics and supportive care programs to improve long-term patient outcomes.

Global Cyclic Neutropenia Treatment Market Dynamics

Key Market Driver: Increasing Prevalence of Rare Hematological Disorders and Growing Access to Biologic Therapies

The increasing prevalence of rare blood disorders and recurrent immune-related infections is driving demand for effective cyclic neutropenia treatments globally. Growing clinical adoption of G-CSF therapies such as filgrastim and pegfilgrastim has significantly improved disease management by reducing severe infections and hospitalization rates. Pharmaceutical companies are also expanding investment in orphan drug development and hematology research programs. Improved reimbursement support in developed markets, particularly across North America and Europe, is further accelerating treatment accessibility and long-term therapy adherence.

Key Restraint/Challenge: High Treatment Costs and Limited Awareness in Developing Regions

A major challenge in the global cyclic neutropenia treatment market is the high cost associated with biologic therapies, genetic testing, and long-term disease monitoring. Advanced treatments including G-CSF injections and bone marrow transplantation procedures often require continuous specialist supervision and frequent laboratory testing, increasing overall healthcare expenditure. For instance, long-term filgrastim therapy can cost several thousand dollars annually per patient depending on dosage frequency and healthcare coverage. In many low- and middle-income countries, limited awareness of rare neutropenia disorders and insufficient access to hematology specialists continue to delay diagnosis and treatment initiation. The limited availability of orphan drugs in emerging healthcare systems further restricts market penetration.

Key Market Opportunity: Integration of AI and Autonomous Vehicle Validation Platforms

The growing focus on precision medicine and rare disease management presents significant opportunities for the cyclic neutropenia treatment market. Advances in genomic sequencing, biomarker-based diagnostics, and personalized biologic therapies are supporting the development of more targeted treatment approaches. For instance, increasing investments in rare disease genomic programs across the U.S., Germany, and Japan are improving early identification of ELANE gene mutations linked to cyclic neutropenia. In addition, collaborations between biotechnology firms and research organizations for orphan drug development are accelerating innovation in hematology therapeutics. Expanding healthcare infrastructure and improving access to specialty care in Asia-Pacific and Latin America are also creating new growth opportunities for treatment providers and pharmaceutical manufacturers.

Global Cyclic Neutropenia Treatment Market Scope

The Cyclic Neutropenia Treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users, and distribution channel.

By Treatment

On the basis of treatment, the global Cyclic Neutropenia Treatment market is segmented into antibiotics, corticosteroids, granulocyte colony-stimulating factor (G-CSF), bone marrow transplant, genetic counseling, and others. The Granulocyte Colony-Stimulating Factor (G-CSF) segment dominated the market with a 44.18% share in 2025 due to its high effectiveness in stimulating neutrophil production and reducing the frequency of severe infections associated with cyclic neutropenia. High adoption is supported by increasing physician preference for biologic therapies, growing availability of recombinant G-CSF products, and strong clinical evidence demonstrating improved patient outcomes. In addition, rising awareness regarding rare hematological disorders, expanding reimbursement support for orphan drugs, and increasing long-term disease management programs are reinforcing segment dominance. Pharmaceutical companies are also investing in advanced biologic formulations and supportive care therapies to improve treatment accessibility and patient compliance. The growing prevalence of recurrent bacterial infections and immune deficiencies further accelerates demand for G-CSF therapy across hospitals and specialty hematology clinics globally.

The Bone Marrow Transplant segment is expected to witness the fastest CAGR of 7.3% from 2026 to 2033, driven by increasing adoption in severe and treatment-resistant cyclic neutropenia cases. Growth is further supported by advancements in stem cell transplantation procedures, improved donor matching technologies, and rising investment in regenerative medicine and hematology research programs globally. Increasing success rates of hematopoietic stem cell transplantation and expanding availability of specialized transplant centers are improving patient outcomes and treatment accessibility. In addition, growing awareness regarding curative treatment options for congenital and inherited neutropenia disorders is accelerating segment demand. Government support for rare disease treatment programs and expanding clinical research initiatives in cellular therapies are further contributing to market expansion. Healthcare providers are increasingly recommending bone marrow transplantation for patients showing poor response to conventional G-CSF therapy. Rising investments in immunology and gene-based therapeutic research are also strengthening innovation in transplantation procedures. Furthermore, technological advancements in post-transplant infection management and supportive care therapies are improving survival rates and encouraging wider adoption globally.

By Diagnosis

On the basis of diagnosis, the global Cyclic Neutropenia Treatment market is segmented into blood tests, genetic test, and others. The Blood Tests segment dominated the market with a share of 42.36% in 2025 due to its widespread use in routine monitoring of neutrophil levels and early detection of cyclic neutropenia episodes. High adoption is supported by cost-effectiveness, easy accessibility, and growing implementation across hospitals, diagnostic laboratories, and hematology clinics. Blood tests remain the primary diagnostic tool for tracking fluctuations in neutrophil counts and evaluating infection risks in patients. In addition, increasing healthcare awareness, improved laboratory infrastructure, and rising adoption of automated hematology analyzers are supporting segment growth. Physicians continue to rely heavily on blood testing for continuous patient monitoring and treatment response assessment. The increasing prevalence of recurrent infections and immune-related disorders further contributes to the strong demand for blood-based diagnostic procedures globally.

The Genetic Test segment is expected to witness the fastest CAGR of 7.1% from 2026 to 2033, driven by growing adoption of precision medicine and increasing identification of ELANE gene mutations linked to cyclic neutropenia. Rising investments in genomic sequencing technologies and rare disease diagnostics are further accelerating segment expansion. Increasing awareness regarding inherited neutropenia disorders and advancements in molecular diagnostic techniques are supporting early and accurate disease identification. Healthcare providers are increasingly integrating genetic testing into hematology diagnostic workflows to improve treatment planning and personalized disease management. In addition, expanding government funding for rare disease research and growing collaborations between biotechnology companies and diagnostic laboratories are strengthening segment growth. The availability of next-generation sequencing platforms and declining costs of genetic analysis are improving accessibility across developed and emerging healthcare markets. Growing emphasis on preventive healthcare and family-based genetic screening programs is also contributing to increased adoption of genetic testing solutions globally.

By Symptoms

On the basis of symptoms, the global Cyclic Neutropenia Treatment market is segmented into fever, recurring gum problems and loose teeth, skin infections, sore throat, lung infections, sores in the mouth, digestive system infections, fatigue, overall feeling of not being well, and others. The Fever segment dominated the market with a share of 21.84% in 2025 due to its high prevalence as one of the earliest and most common clinical manifestations of cyclic neutropenia. Increasing patient admissions associated with recurrent fever episodes and infection-related complications are supporting strong segment demand. Physicians and healthcare providers prioritize fever monitoring for early diagnosis and disease progression assessment, contributing to higher treatment adoption. In addition, rising awareness regarding immune deficiencies and infection-related hematological disorders is improving clinical screening rates globally. The growing burden of recurrent bacterial infections among pediatric and adult populations further reinforces the dominance of this segment in the market.

The Skin Infections segment is expected to witness the fastest CAGR of 6.8% from 2026 to 2033, driven by increasing incidence of bacterial skin complications associated with low neutrophil counts and growing emphasis on infection management therapies. Rising prevalence of severe skin abscesses, cellulitis, and recurrent bacterial infections among cyclic neutropenia patients is accelerating treatment demand globally. Healthcare providers are increasingly adopting targeted antibiotic therapies and supportive care approaches to manage skin-related complications effectively. In addition, growing awareness regarding infection prevention and early dermatological intervention is supporting segment expansion. Advancements in antimicrobial therapies and improved access to specialty dermatology and hematology services are further contributing to market growth. Increasing hospitalization rates due to untreated skin infections and immune-related complications are also strengthening demand for advanced therapeutic solutions. Furthermore, expanding healthcare infrastructure and rising investment in rare disease treatment programs are positively influencing segment development across global markets.

By Dosage

On the basis of dosage, the global Cyclic Neutropenia Treatment market is segmented into injection, tablets, and others. The Injection segment dominated the market with a share of 60.34% in 2025 due to the widespread clinical use of injectable Granulocyte Colony-Stimulating Factor (G-CSF) therapies for effective neutrophil stimulation and rapid infection control. High adoption is supported by strong physician preference for biologic injections in severe cyclic neutropenia cases requiring immediate therapeutic response. In addition, increasing availability of advanced injectable biologics, rising hospital-based administration, and growing long-term supportive care programs are reinforcing segment dominance. Pharmaceutical companies are expanding production of injectable hematology therapeutics to address rising patient demand and improve treatment accessibility globally. The growing prevalence of recurrent infections and immune dysfunction disorders is further accelerating the demand for injectable therapies across specialty hematology centers and hospitals.

The Tablets segment is expected to witness the fastest CAGR of 6.7% from 2026 to 2033, driven by rising demand for convenient oral therapies, improved patient compliance, and ongoing development of oral supportive care medications. Increasing preference for home-based treatment approaches and reduced dependency on hospital-administered injections are supporting segment growth globally. Pharmaceutical companies are investing in advanced oral formulations to improve treatment convenience and long-term disease management outcomes. In addition, growing awareness regarding patient-centric healthcare and improved medication adherence is accelerating adoption of tablet-based therapies. Expanding retail and online pharmacy networks are also improving accessibility of oral medications across emerging healthcare markets. Advancements in oral drug delivery technologies and increasing research activities focused on supportive neutropenia therapies are further contributing to segment expansion. Furthermore, rising healthcare expenditure and growing focus on reducing hospitalization costs are strengthening the demand for tablet-based treatment options worldwide.

By Route of Administration

On the basis of route of administration, the global Cyclic Neutropenia Treatment market is segmented into oral, intravenous, and others. The Intravenous segment dominated the market with a share of 57.89% in 2025 due to its high effectiveness in delivering rapid therapeutic response during severe infection episodes and neutropenia management. Hospitals and specialty hematology centers widely utilize intravenous administration for biologic therapies and emergency supportive care treatments. High adoption is further supported by increasing hospitalization rates related to recurrent infections and immune complications. In addition, advancements in infusion therapies, expanding healthcare infrastructure, and growing access to specialized treatment facilities are strengthening segment growth. Physicians continue to prefer intravenous administration in critically ill patients requiring immediate neutrophil recovery and intensive clinical monitoring.

The Oral segment is expected to witness the fastest CAGR of 6.5% from 2026 to 2033, driven by increasing adoption of oral supportive therapies, greater treatment convenience, and improving patient adherence in long-term disease management. Rising preference for home-based healthcare and self-administered medications is supporting strong demand for oral treatment options globally. Pharmaceutical companies are focusing on the development of advanced oral formulations that improve bioavailability and therapeutic effectiveness. In addition, expanding retail and online pharmacy penetration is improving accessibility of oral medications across developed and emerging healthcare markets. Increasing awareness regarding patient-centric treatment approaches and cost-effective disease management solutions is further accelerating segment growth. Growing elderly population and rising prevalence of chronic immune disorders are also contributing to higher adoption of oral therapies. Furthermore, advancements in oral drug delivery systems and supportive care therapeutics are strengthening long-term market expansion.

By End-Users

On the basis of end-users, the global Cyclic Neutropenia Treatment market is segmented into clinic, hospital, and others. The Hospital segment dominated the market with a share of 48.05% in 2025 due to the high availability of advanced hematology care infrastructure, specialized physicians, and comprehensive infection management facilities. Hospitals remain the primary treatment centers for cyclic neutropenia patients requiring biologic therapies, intravenous administration, and continuous clinical monitoring. Increasing patient admissions related to severe infection episodes and immune deficiencies are further supporting segment growth. In addition, rising healthcare investments, improved access to advanced diagnostics, and growing adoption of orphan drug therapies are reinforcing the dominance of hospitals globally. Strong reimbursement coverage and multidisciplinary treatment approaches are also contributing to increased patient preference for hospital-based care settings.

The Clinic segment is expected to witness the fastest CAGR of 6.6% from 2026 to 2033, driven by increasing availability of outpatient hematology services, growing patient preference for cost-effective care, and expanding specialty clinic networks globally. Rising adoption of early-stage diagnostic services and supportive care treatments in clinics is contributing to segment expansion. Healthcare providers are increasingly establishing specialized hematology and rare disease clinics to improve patient accessibility and reduce hospital burden. In addition, shorter waiting times, lower treatment costs, and personalized patient management are supporting the growing preference for clinic-based care settings. Expanding healthcare infrastructure in emerging economies and rising investment in outpatient treatment facilities are further accelerating segment growth. Technological advancements in diagnostic tools and remote patient monitoring solutions are also enhancing clinical efficiency and treatment quality. Furthermore, increasing awareness regarding early disease management and preventive healthcare practices is positively influencing demand for clinic-based cyclic neutropenia treatment services worldwide.

By Distribution Channel

On the basis of distribution channel, the global Cyclic Neutropenia Treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The Hospital Pharmacy segment dominated the market with a share of 55.12% in 2025 due to strong in-hospital dispensing of injectable biologics, supportive therapies, and emergency infection management medications. High adoption is supported by increasing hospitalization rates, availability of specialty biologic drugs, and continuous physician supervision during treatment administration. In addition, hospitals maintain advanced cold-chain storage infrastructure and regulatory compliance systems necessary for handling sensitive biologic therapies. Rising demand for coordinated treatment management and integrated patient monitoring programs is further reinforcing the segment’s leading market position globally.

The Online Pharmacy segment is expected to witness the fastest CAGR of 6.9% from 2026 to 2033, driven by growing digital healthcare adoption, increasing accessibility of specialty medications, and rising preference for convenient home-based pharmaceutical purchasing services. Expanding internet penetration and rising smartphone usage are supporting the rapid growth of online pharmacy platforms globally. Patients are increasingly preferring digital purchasing channels due to convenience, doorstep delivery services, and competitive pricing advantages. In addition, growing integration of e-prescriptions, telemedicine platforms, and digital payment systems is improving accessibility and operational efficiency across online pharmacy networks. Pharmaceutical companies and healthcare providers are also strengthening partnerships with digital pharmacy platforms to expand patient reach and improve treatment continuity. Rising awareness regarding chronic disease management and long-term medication adherence is further contributing to segment growth. Furthermore, supportive regulatory developments and expanding healthcare e-commerce infrastructure are accelerating adoption of online pharmaceutical distribution channels worldwide.

Global Cyclic Neutropenia Treatment Market Regional Analysis

North America dominated the Cyclic Neutropenia Treatment market and accounted for the largest revenue share of 36.42% in 2025, supported by advanced healthcare infrastructure, strong orphan drug availability, and increasing adoption of biologic therapies. The region also benefits from the presence of leading pharmaceutical companies, expanding access to genetic testing, and growing awareness regarding rare hematological disorders. Increasing investments in precision medicine, supportive reimbursement policies, and rising demand for Granulocyte Colony-Stimulating Factor (G-CSF) therapies continue to strengthen North America’s leadership position in the global market.

U.S. Cyclic Neutropenia Treatment Market Insight

The U.S. Cyclic Neutropenia Treatment market is witnessing strong growth due to rising adoption of biologic therapies, increasing investments in rare disease research, and expanding access to advanced diagnostic technologies. The country’s well-established healthcare infrastructure, strong presence of hematology specialists, and favorable reimbursement support for orphan drugs are driving market demand. In addition, growing awareness regarding inherited neutropenia disorders and increasing utilization of genetic testing are accelerating early diagnosis and long-term disease management across the country.

Europe Cyclic Neutropenia Treatment Market Insight

The Europe Cyclic Neutropenia Treatment market remains a major contributor to global revenue, driven by strong healthcare systems, increasing government support for rare disease treatment, and rising adoption of advanced biologic therapies. The widespread availability of hematology care centers, expanding genomic research initiatives, and growing focus on early diagnosis are supporting market expansion across the region. Increasing investments in orphan drug development and personalized medicine continue to strengthen treatment accessibility and patient outcomes throughout Europe.

U.K. Cyclic Neutropenia Treatment Market Insight

The U.K. Cyclic Neutropenia Treatment market is experiencing steady growth, supported by increasing awareness regarding rare blood disorders, rising adoption of genetic testing, and growing access to specialized hematology care services. Expanding healthcare investments and strong focus on early disease diagnosis are contributing to market growth. Furthermore, ongoing advancements in biologic therapies and supportive government initiatives for orphan disease management are improving treatment accessibility and long-term patient care across the country.

Germany Cyclic Neutropenia Treatment Market Insight

The Germany Cyclic Neutropenia Treatment market is expanding steadily due to the country’s advanced healthcare infrastructure, strong pharmaceutical manufacturing base, and increasing investment in rare disease research. Hospitals, specialty clinics, and research institutes are increasingly adopting advanced diagnostic tools and biologic therapies for cyclic neutropenia management. Continuous advancements in genomic testing, precision medicine, and supportive care treatments, along with strong government healthcare support, are further driving market growth in Germany.

Asia-Pacific Cyclic Neutropenia Treatment Market Insight

The Asia-Pacific Cyclic Neutropenia Treatment market is expected to witness rapid growth at a CAGR of 7.4% from 2026 to 2033, driven by improving healthcare access, rising awareness regarding rare blood disorders, and expanding diagnostic capabilities across China, India, and Japan. Growing healthcare expenditure, increasing availability of biologic therapies, and rising adoption of genetic testing are supporting regional market expansion. In addition, improving healthcare infrastructure and increasing focus on early diagnosis and rare disease management are accelerating treatment adoption across the region.

Japan Cyclic Neutropenia Treatment Market Insight

The Japan Cyclic Neutropenia Treatment market is witnessing consistent growth due to rising investments in advanced hematology treatments, increasing adoption of precision medicine, and growing awareness regarding inherited neutropenia disorders. Hospitals and research institutes are increasingly utilizing genomic testing and biologic therapies for disease diagnosis and management. Moreover, supportive healthcare policies and the country’s strong focus on advanced medical innovation are further contributing to market growth.

China Cyclic Neutropenia Treatment Market Insight

The China Cyclic Neutropenia Treatment market is growing rapidly, driven by expanding healthcare infrastructure, increasing awareness regarding rare hematological disorders, and rising government focus on improving access to advanced treatment solutions. Growing adoption of genetic testing technologies and increasing availability of biologic therapies across hospitals and specialty clinics are significantly boosting market demand. In addition, rising healthcare investments, expanding pharmaceutical manufacturing capabilities, and improving rare disease management programs are positioning China as one of the fastest-growing markets for Cyclic Neutropenia Treatment globally.

Global Cyclic Neutropenia Treatment Market Share

The Cyclic Neutropenia Treatment industry is primarily led by well-established companies, including:

• Amgen Inc. (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Sanofi S.A. (France)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Baxter International Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Eli Lilly and Company (U.S.)
• AstraZeneca PLC (U.K.)
• CSL Limited (Australia)
• Biogen Inc. (U.S.)
• Sobi (Sweden)
• Aptevo Therapeutics Inc. (U.S.)
• Partner Therapeutics, Inc. (U.S.)
• Kyowa Kirin Co., Ltd. (Japan)
• Coherus BioSciences, Inc. (U.S.)
• Cipla Limited (India)
• Dr. Reddy’s Laboratories Ltd. (India)
• Lupin Limited (India)
• Zydus Lifesciences Limited (India)
• Intas Pharmaceuticals Ltd. (India)
• Accord Healthcare (U.K.)
• Fresenius Kabi AG (Germany)
• Hikma Pharmaceuticals PLC (U.K.)

Latest Developments in Global Cyclic Neutropenia Treatment Market

• In June 2021, the European Medicines Agency (EMA) published updated assessment and regulatory information for Filgrastim Hexal, reinforcing the continued clinical use of filgrastim biosimilars in severe chronic neutropenia, including cyclic neutropenia management. The development highlighted growing regulatory confidence in biosimilar-based hematology therapies across Europe
• In February 2022, the U.S. Food and Drug Administration (FDA) approved Releuko (filgrastim-ayow), a biosimilar to Neupogen developed by Amneal Pharmaceuticals, for the treatment of severe chronic neutropenia, including cyclic neutropenia. The approval expanded access to cost-effective granulocyte colony-stimulating factor (G-CSF) therapies and strengthened the availability of biologic treatment options for patients with rare neutropenia disorders
• In November 2023, the FDA approved RYZNEUTA (efbemalenograstim alfa), developed by Evive Biotechnology, for reducing the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy. The approval reflected broader advancements in long-acting G-CSF therapies, which are increasingly influencing innovation in neutropenia treatment and supportive hematology care markets
• In March 2025, the European Medicines Agency (EMA) announced marketing authorization for Zefylti (filgrastim), a biologic therapy indicated for neutropenia management, including severe chronic neutropenia conditions. The approval strengthened the European market for advanced filgrastim therapies and highlighted ongoing expansion in biologic treatment accessibility
• In February 2026, Accord BioPharma announced that the FDA approved FILKRI (filgrastim-laha), a biosimilar to Neupogen, for multiple neutropenia-related indications, including severe chronic neutropenia such as cyclic neutropenia. The launch expanded the company’s granulocyte colony-stimulating factor (G-CSF) biosimilar portfolio and increased treatment availability for neutropenia patients globally

SKU-67567